Volume 15 Issue 4
May  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Analysis  > 2025  >  15(4): 101146
Lei Xu, Tao Zhang, Baojie Zhu, Honglin Tao, Yue Liu, Xianfeng Liu, Yi Zhang, Xianli Meng. Mitochondrial quality control disorder in neurodegenerative disorders: Potential and advantages of traditional Chinese medicines[J]. Journal of Pharmaceutical Analysis, 2025, 15(4): 101146. doi: 10.1016/j.jpha.2024.101146
Citation: Lei Xu, Tao Zhang, Baojie Zhu, Honglin Tao, Yue Liu, Xianfeng Liu, Yi Zhang, Xianli Meng. Mitochondrial quality control disorder in neurodegenerative disorders: Potential and advantages of traditional Chinese medicines[J]. Journal of Pharmaceutical Analysis, 2025, 15(4): 101146. doi: 10.1016/j.jpha.2024.101146
shu

Mitochondrial quality control disorder in neurodegenerative disorders: Potential and advantages of traditional Chinese medicines

doi: 10.1016/j.jpha.2024.101146

  • a. State Key Laboratory of Southwestern Chinese Medicine Resources, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China;

  • b. College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China;

  • c. School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China;

  • d. Meishan Hospital of Chengdu University of Traditional Chinese Medicine, Meishan, Sichuan, 620032, China

Funds:

This work was supported by the Natural Science Foundation of China (Grant No.: 82130113), the “Xinglin Scholars” Research Promotion Program of Chengdu University of Traditional Chinese Medicine, China (Program No.: ZDZX2022005), the China Postdoctoral Science Foundation (Grant No.: 2021MD703800), and the Science Foundation for Youths of Science &

Technology Department of Sichuan Province, China (Grant No.: 2022NSFSC1449).

  • Received Date: Jul. 12, 2024
  • Accepted Date: Nov. 10, 2024
  • Rev Recd Date: Oct. 31, 2024
  • Publish Date: Nov. 14, 2024
    Abstract
  • Neurodegenerative disorders (NDDs) are prevalent chronic conditions characterized by progressive synaptic loss and pathological protein alterations. Increasing evidence suggested that mitochondrial quality control (MQC) serves as the key cellular process responsible for clearing misfolded proteins and impaired mitochondria. Herein, we provided a comprehensive analysis of the mechanisms through which MQC mediates the onset and progression of NDDs, emphasizing mitochondrial dynamic stability, the clearance of damaged mitochondria, and the generation of new mitochondria. In addition, traditional Chinese medicines (TCMs) and their active monomers targeting MQC in NDD treatment have been demonstrated. Consequently, we compiled the TCMs that show great potential in the treatment of NDDs by targeting MQC, aiming to offer novel insights and a scientific foundation for the use of MQC stabilizers in NDD prevention and treatment.
    • FullText(HTML)
  • loading
    • References(197)
  • [1]
    D.M. Teleanu, A.G. Niculescu, I.I. Lungu, et al., An overview of oxidative stress, neuroinflammation, and neurodegenerative diseases, Int. J. Mol. Sci. 23 (2022), 5938.
    [2]
    World Health Organization. Parkinson’s disease: A public health approach: Technical brief. https://www.who.int/publications/i/item/9789240050983/. (Accessed 24 June 2022).
    [3]
    R. Al-Kharboosh, J.J. Perera, A. Bechtle, et al., Emerging point-of-care autologous cellular therapy using adipose-derived stromal vascular fraction for neurodegenerative diseases, Clin. Transl. Med. 12 (2022), e1093.
    [4]
    R. Hussain, H. Zubair, S. Pursell, et al., Neurodegenerative diseases: Regenerative mechanisms and novel therapeutic approaches, Brain Sci. 8 (2018), 177.
    [5]
    M. Mistretta, A. Farini, Y. Torrente, et al., Multifaceted nanoparticles: Emerging mechanisms and therapies in neurodegenerative diseases, Brain 146 (2023) 2227-2240.
    [6]
    M.A. Eldeeb, R.A. Thomas, M.A. Ragheb, et al., Mitochondrial quality control in health and in Parkinson’s disease, Physiol. Rev. 102 (2022) 1721-1755.
    [7]
    G.E. Choi, H.J. Han, Glucocorticoid impairs mitochondrial quality control in neurons, Neurobiol. Dis. 152 (2021), 105301.
    [8]
    P. Cilleros-Holgado, D. Gomez-Fernandez, R. Pinero-Perez, et al., Mitochondrial quality control via mitochondrial unfolded protein response (mtUPR) in ageing and neurodegenerative diseases, Biomolecules 13 (2023), 1789.
    [9]
    H. Xu, Y. Liu, L. Li, et al., Sirtuins at the crossroads between mitochondrial quality control and neurodegenerative diseases: Structure, regulation, modifications, and modulators, Aging Dis. 14 (2023) 794-824.
    [10]
    X. Yan, B. Wang, Y. Hu, et al., Abnormal mitochondrial quality control in neurodegenerative diseases, Front. Cell. Neurosci. 14 (2020), 138.
    [11]
    A. Roca-Portoles, S.W.G. Tait, Mitochondrial quality control: From molecule to organelle, Cell. Mol. Life Sci. 78 (2021) 3853-3866.
    [12]
    P. Mensah-Kane, N. Sumien, The potential of hyperbaric oxygen as a therapy for neurodegenerative diseases, Geroscience 45 (2023) 747-756.
    [13]
    F. Duraes, M. Pinto, E. Sousa, Old drugs as new treatments for neurodegenerative diseases, Pharmaceuticals (Basel) 11 (2018), 44.
    [14]
    J. Koschel, K. Ray Chaudhuri, L. Tonges, et al., Implications of dopaminergic medication withdrawal in Parkinson’s disease, J. Neural Transm. (Vienna) 129 (2022) 1169-1178.
    [15]
    P. Sivanandy, T.C. Leey, T.C. Xiang, et al., Systematic review on Parkinson’s disease medications, emphasizing on three recently approved drugs to control Parkinson’s symptoms, Int. J. Environ. Res. Public Health 19 (2021), 364.
    [16]
    J. Dong, Y. Cui, S. Li, et al., Current pharmaceutical treatments and alternative therapies of Parkinson’s disease, Curr. Neuropharmacol. 14 (2016) 339-355.
    [17]
    I. Solanki, P. Parihar, M.S. Parihar, Neurodegenerative diseases: From available treatments to prospective herbal therapy, Neurochem. Int. 95 (2016) 100-108.
    [18]
    X. Chen, W. Pan, The treatment strategies for neurodegenerative diseases by integrative medicine, Integr. Med. Int. 1 (2015) 223-225.
    [19]
    C. Ricci, Neurodegenerative disease: From molecular basis to therapy, Int. J. Mol. Sci. 25 (2024), 967.
    [20]
    N. Pfanner, B. Warscheid, N. Wiedemann, Mitochondrial proteins: From biogenesis to functional networks, Nat. Rev. Mol. Cell Biol. 20 (2019) 267-284.
    [21]
    D.H. Mendelsohn, K. Schnabel, A. Mamilos, et al., Structural analysis of mitochondrial dynamics-from cardiomyocytes to osteoblasts: A critical review, Int. J. Mol. Sci. 23 (2022), 4571.
    [22]
    M. Krols, B. Asselbergh, R. De Rycke, et al., Sensory neuropathy-causing mutations in ATL3 affect ER-mitochondria contact sites and impair axonal mitochondrial distribution, Hum. Mol. Genet. 28 (2019) 615-627.
    [23]
    D. Larrea, M. Pera, A. Gonnelli, et al., MFN2 mutations in Charcot-Marie-Tooth disease alter mitochondria-associated ER membrane function but do not impair bioenergetics, Hum. Mol. Genet. 28 (2019) 1782-1800.
    [24]
    J.E. Lee, L.M. Westrate, H. Wu, et al., Multiple dynamin family members collaborate to drive mitochondrial division, Nature 540 (2016) 139-143.
    [25]
    A.M. Labrousse, M.D. Zappaterra, D.A. Rube, et al., C. elegans dynamin-related protein DRP-1 controls severing of the mitochondrial outer membrane, Mol. Cell 4 (1999) 815-826.
    [26]
    O.C. Loson, Z. Song, H. Chen, et al., Fis1, Mff, MiD49, and MiD51 mediate Drp1 recruitment in mitochondrial fission, Mol. Biol. Cell 24 (2013) 659-667.
    [27]
    M. Zerihun, S. Sukumaran, N. Qvit, The Drp1-mediated mitochondrial fission protein interactome as an emerging core player in mitochondrial dynamics and cardiovascular disease therapy, Int. J. Mol. Sci. 24 (2023), 5785.
    [28]
    J. Hu, Y. Zhang, X. Jiang, et al., ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine, J. Exp. Clin. Cancer Res. 38 (2019), 225.
    [29]
    H. Otera, N. Miyata, O. Kuge, et al., Drp1-dependent mitochondrial fission via MiD49/51 is essential for apoptotic cristae remodeling, J. Cell Biol. 212 (2016) 531-544.
    [30]
    T. Song, X. Song, C. Zhu, et al., Mitochondrial dysfunction, oxidative stress, neuroinflammation, and metabolic alterations in the progression of Alzheimer’s disease: A meta-analysis of in vivo magnetic resonance spectroscopy studies, Ageing Res. Rev. 72 (2021), 101503.
    [31]
    J. Balog, S.L. Mehta, R. Vemuganti, Mitochondrial fission and fusion in secondary brain damage after CNS insults, J. Cereb. Blood Flow Metab. 36 (2016) 2022-2033.
    [32]
    J. Gao, L. Wang, J. Liu, et al., Abnormalities of mitochondrial dynamics in neurodegenerative diseases, Antioxidants (Basel) 6 (2017), 25.
    [33]
    H. Grel, D. Woznica, K. Ratajczak, et al., Mitochondrial dynamics in neurodegenerative diseases: Unraveling the role of fusion and fission processes, Int. J. Mol. Sci. 24 (2023), 13033.
    [34]
    C. Larrue, S. Mouche, S. Lin, et al., Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia, Leukemia 37 (2023) 765-775.
    [35]
    A.H. Pham, S. Meng, Q.N. Chu, et al., Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit, Hum. Mol. Genet. 21 (2012) 4817-4826.
    [36]
    H. Chen, S.A. Detmer, A.J. Ewald, et al., Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development, J. Cell Biol. 160 (2003) 189-200.
    [37]
    C. Brooks, S.G. Cho, C. Wang, et al., Fragmented mitochondria are sensitized to Bax insertion and activation during apoptosis, Am. J. Physiol. Cell Physiol. 300 (2011) C447-C455.
    [38]
    V. Del Dotto, P. Mishra, S. Vidoni, et al., OPA1 isoforms in the hierarchical organization of mitochondrial functions, Cell Rep. 19 (2017) 2557-2571.
    [39]
    R. Gilkerson, P.D.L. Torre, S. St Vallier, Mitochondrial OMA1 and OPA1 as gatekeepers of organellar structure/function and cellular stress response, Front. Cell Dev. Biol. 9 (2021), 626117.
    [40]
    R. Sanchez-Rodriguez, C. Tezze, A.H.R. Agnellini, et al., OPA1 drives macrophage metabolism and functional commitment via p65 signaling, Cell Death Differ. 30 (2023) 742-752.
    [41]
    Y. Yu, H.C. Lee, K.C. Chen, et al., Inner membrane fusion mediates spatial distribution of axonal mitochondria, Sci. Rep. 6 (2016), 18981.
    [42]
    T. Misgeld, T.L. Schwarz, Mitostasis in neurons: Maintaining mitochondria in an extended cellular architecture, Neuron 96 (2017) 651-666.
    [43]
    A. Mandal, H.C. Wong, K. Pinter, et al., Retrograde mitochondrial transport is essential for organelle distribution and health in zebrafish neurons, J. Neurosci. 41 (2021) 1371-1392.
    [44]
    B. Sharma, D. Pal, U. Sharma, et al., Mitophagy: An emergence of new player in Alzheimer’s disease, Front. Mol. Neurosci. 15 (2022), 921908.
    [45]
    J. Wang, C. Xu, Astrocytes autophagy in aging and neurodegenerative disorders, Biomed. Pharmacother. 122 (2020), 109691.
    [46]
    A. Fleming, M. Bourdenx, M. Fujimaki, et al., The different autophagy degradation pathways and neurodegeneration, Neuron 110 (2022) 935-966.
    [47]
    W. Li, P. He, Y. Huang, et al., Selective autophagy of intracellular organelles: Recent research advances, Theranostics 11 (2021) 222-256.
    [48]
    J.D. Magalhaes, L. Fao, R. Vilaca, et al., Macroautophagy and mitophagy in neurodegenerative disorders: Focus on therapeutic interventions, Biomedicines 9 (2021), 1625.
    [49]
    D. Glick, S. Barth, K.F. MacLeod, Autophagy: Cellular and molecular mechanisms, J. Pathol. 221 (2010) 3-12.
    [50]
    M. Onishi, K. Yamano, M. Sato, et al., Molecular mechanisms and physiological functions of mitophagy, EMBO J. 40 (2021), e104705.
    [51]
    D.A. Chistiakov, T.P. Shkurat, A.A. Melnichenko, et al., The role of mitochondrial dysfunction in cardiovascular disease: A brief review, Ann. Med. 50 (2018) 121-127.
    [52]
    L.E. Fritsch, M.E. Moore, S.A. Sarraf, et al., Ubiquitin and receptor-dependent mitophagy pathways and their implication in neurodegeneration, J. Mol. Biol. 432 (2020) 2510-2524.
    [53]
    Z.D. Zhou, S. Sathiyamoorthy, D.C. Angeles, et al., Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson’s disease (PD), Mol. Brain 9 (2016), 41.
    [54]
    A. Hamacher-Brady, N.R. Brady, Mitophagy programs: Mechanisms and physiological implications of mitochondrial targeting by autophagy, Cell. Mol. Life Sci. 73 (2016) 775-795.
    [55]
    J.S. Kerr, B.A. Adriaanse, N.H. Greig, et al., Mitophagy and Alzheimer’s disease: Cellular and molecular mechanisms, Trends Neurosci. 40 (2017) 151-166.
    [56]
    A. Rakovic, J. Ziegler, C.U. Martensson, et al., PINK1-dependent mitophagy is driven by the UPS and can occur independently of LC3 conversion, Cell Death Differ. 26 (2019) 1428-1441.
    [57]
    Q. Cai, P. Tammineni, Alterations in mitochondrial quality control in Alzheimer’s disease, Front. Cell. Neurosci. 10 (2016), 24.
    [58]
    K. Kaarniranta, J. Blasiak, P. Liton, et al., Autophagy in age-related macular degeneration, Autophagy 19 (2023) 388-400.
    [59]
    L.P. Poole, K.F. MacLeod, Mitophagy in tumorigenesis and metastasis, Cell. Mol. Life Sci. 78 (2021) 3817-3851.
    [60]
    M. Di Rienzo, A. Romagnoli, F. Ciccosanti, et al., AMBRA1 regulates mitophagy by interacting with ATAD3A and promoting PINK1 stability, Autophagy 18 (2022) 1752-1762.
    [61]
    L.P. Wilhelm, J. Zapata-Munoz, B. Villarejo-Zori, et al., BNIP3L/NIX regulates both mitophagy and pexophagy, EMBO J. 41 (2022), e111115.
    [62]
    J. Sassone, C. Colciago, P. Marchi, et al., Mutant Huntingtin induces activation of the Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3), Cell Death Dis. 1 (2010), e7.
    [63]
    A. Di Rita, P. D’Acunzo, L. Simula, et al., AMBRA1-mediated mitophagy counteracts oxidative stress and apoptosis induced by neurotoxicity in human neuroblastoma SH-SY5Y cells, Front. Cell. Neurosci. 12 (2018), 92.
    [64]
    B. Khalil, N. El Fissi, A. Aouane, et al., PINK1-induced mitophagy promotes neuroprotection in Huntington’s disease, Cell Death Dis. 6 (2015), e1617.
    [65]
    Z. Wu, A. Wu, J. Dong, et al., Grape skin extract improves muscle function and extends lifespan of a Drosophila model of Parkinson’s disease through activation of mitophagy, Exp. Gerontol. 113 (2018) 10-17.
    [66]
    S.M. Raefsky, M.P. Mattson, Adaptive responses of neuronal mitochondria to bioenergetic challenges: Roles in neuroplasticity and disease resistance, Free Radic. Biol. Med. 102 (2017) 203-216.
    [67]
    R.C. Scarpulla, Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network, Biochim. Biophys. Acta 1813 (2011) 1269-1278.
    [68]
    P.A. Li, X. Hou, S. Hao, Mitochondrial biogenesis in neurodegeneration, J. Neurosci. Res. 95 (2017) 2025-2029.
    [69]
    H.S. Hillen, D. Temiakov, P. Cramer, Structural basis of mitochondrial transcription, Nat. Struct. Mol. Biol. 25 (2018) 754-765.
    [70]
    B. Leaw, S. Nair, R. Lim, et al., Mitochondria, bioenergetics and excitotoxicity: New therapeutic targets in perinatal brain injury, Front. Cell. Neurosci. 11 (2017), 199.
    [71]
    Y. Kang, L.F. Fielden, D. Stojanovski, Mitochondrial protein transport in health and disease, Semin. Cell Dev. Biol. 76 (2018) 142-153.
    [72]
    P. Guedes-Dias, B.R. Pinho, T.R. Soares, et al., Mitochondrial dynamics and quality control in Huntington’s disease, Neurobiol. Dis. 90 (2016) 51-57.
    [73]
    S. Kaushik, A.M. Cuervo, Proteostasis and aging, Nat. Med. 21 (2015) 1406-1415.
    [74]
    P. Chopade, N. Chopade, Z. Zhao, et al., Alzheimer’s and Parkinson’s disease therapies in the clinic, Bioeng. Transl. Med. 8 (2022), e10367.
    [75]
    M. Fakhoury, Microglia and astrocytes in Alzheimer’s disease: Implications for therapy, Curr. Neuropharmacol. 16 (2018) 508-518.
    [76]
    J. Wang, W. Liu, H. Shi, et al., A role for PGC-1a in the control of abnormal mitochondrial dynamics in Alzheimer’s disease, Cells 11 (2022), 2849.
    [77]
    J. Xing, L. Qi, X. Liu, et al., Roles of mitochondrial fusion and fission in breast cancer progression: A systematic review, World J. Surg. Oncol. 20 (2022), 331.
    [78]
    M. de la Cueva, D. Antequera, L. Ordonez-Gutierrez, et al., Amyloid-β impairs mitochondrial dynamics and autophagy in Alzheimer’s disease experimental models, Sci. Rep. 12 (2022), 10092.
    [79]
    V.K. Medala, B. Gollapelli, S. Dewanjee, et al., Mitochondrial dysfunction, mitophagy, and role of dynamin-related protein 1 in Alzheimer’s disease, J. Neurosci. Res. 99 (2021) 1120-1135.
    [80]
    J. Grohm, S.W. Kim, U. Mamrak, et al., Inhibition of Drp1 provides neuroprotection in vitro and in vivo, Cell Death Differ. 19 (2012) 1446-1458.
    [81]
    L.Y. Shields, H. Li, K. Nguyen, et al., Mitochondrial fission is a critical modulator of mutant APP-induced neural toxicity, J. Biol. Chem. 296 (2021), 100469.
    [82]
    M.E. Ahmed, G.P. Selvakumar, D. Kempuraj, et al., Synergy in disruption of mitochondrial dynamics by Aβ(1-42) and glia maturation factor (GMF) in SH-SY5Y cells is mediated through alterations in fission and fusion proteins, Mol. Neurobiol. 56 (2019) 6964-6975.
    [83]
    X. Wang, B. Su, H.G. Lee, et al., Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease, J. Neurosci. 29 (2009) 9090-9103.
    [84]
    S.H. Baek, S.J. Park, J.I. Jeong, et al., Inhibition of Drp1 ameliorates synaptic depression, Aβ deposition, and cognitive impairment in an Alzheimer’s disease model, J. Neurosci. 37 (2017) 5099-5110.
    [85]
    X. Wang, Y. Xue, Y. Yao, et al., PINK1 regulates mitochondrial fission/fusion and neuroinflammation in β-amyloid-induced Alzheimer’s disease models, Neurochem. Int. 154 (2022), 105298.
    [86]
    P.H. Reddy, M. Manczak, X. Yin, Mitochondria-division inhibitor 1 protects against amyloid-β induced mitochondrial fragmentation and synaptic damage in Alzheimer’s disease, J. Alzheimers Dis. 58 (2017) 147-162.
    [87]
    S.E. Lee, D. Kwon, N. Shin, et al., Accumulation of APP-CTF induces mitophagy dysfunction in the iNSCs model of Alzheimer’s disease, Cell Death Discov. 8 (2022), 1.
    [88]
    L. Vaillant-Beuchot, A. Mary, R. Pardossi-Piquard, et al., Accumulation of amyloid precursor protein C-terminal fragments triggers mitochondrial structure, function, and mitophagy defects in Alzheimer’s disease models and human brains, Acta Neuropathol. 141 (2021) 39-65.
    [89]
    E. Zenaro, G. Piacentino, G. Constantin, The blood-brain barrier in Alzheimer’s disease, Neurobiol. Dis. 107 (2017) 41-56.
    [90]
    X. Liu, M. Ye, L. Ma, The emerging role of autophagy and mitophagy in tauopathies: From pathogenesis to translational implications in Alzheimer’s disease, Front. Aging Neurosci. 14 (2022), 1022821.
    [91]
    M. Eshraghi, A. Adlimoghaddam, A. Mahmoodzadeh, et al., Alzheimer’s disease pathogenesis: Role of autophagy and mitophagy focusing in microglia, Int. J. Mol. Sci. 22 (2021), 3330.
    [92]
    P.H. Reddy, X. Yin, M. Manczak, et al., Mutant APP and amyloid beta-induced defective autophagy, mitophagy, mitochondrial structural and functional changes and synaptic damage in hippocampal neurons from Alzheimer’s disease, Hum. Mol. Genet. 27 (2018) 2502-2516.
    [93]
    E.F. Fang, Y. Hou, K. Palikaras, et al., Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease, Nat. Neurosci. 22 (2019) 401-412.
    [94]
    E.F. Fang, Mitophagy and NAD+ inhibit Alzheimer disease, Autophagy 15 (2019) 1112-1114.
    [95]
    S. Kshirsagar, N. Sawant, H. Morton, et al., Mitophagy enhancers against phosphorylated Tau-induced mitochondrial and synaptic toxicities in Alzheimer disease, Pharmacol. Res. 174 (2021), 105973.
    [96]
    J.A. Pradeepkiran, A. Hindle, S. Kshirsagar, et al., Are mitophagy enhancers therapeutic targets for Alzheimer’s disease? Biomed. Pharmacother. 149 (2022), 112918.
    [97]
    C. Chen, C. Yang, J. Wang, et al., Melatonin ameliorates cognitive deficits through improving mitophagy in a mouse model of Alzheimer’s disease, J. Pineal Res. 71 (2021), e12774.
    [98]
    K. Zeng, X. Yu, Y.A.R. Mahaman, et al., Defective mitophagy and the etiopathogenesis of Alzheimer’s disease, Transl. Neurodegener. 11 (2022), 32.
    [99]
    L. Zhang, Y. Fang, X. Zhao, et al., BRUCE silencing leads to axonal dystrophy by repressing autophagosome-lysosome fusion in Alzheimer’s disease, Transl. Psychiatry 11 (2021), 421.
    [100]
    L. Zhang, Y. Fang, X. Cheng, et al., Interaction between TRPML1 and p62 in regulating autophagosome-lysosome fusion and impeding neuroaxonal dystrophy in Alzheimer’s disease, Oxid. Med. Cell. Longev. 2022 (2022), 8096009.
    [101]
    A. Adlimoghaddam, G.G. Odero, G. Glazner, et al., Nilotinib improves bioenergetic profiling in brain astroglia in the 3xTg mouse model of Alzheimer’s disease, Aging Dis. 12 (2021) 441-465.
    [102]
    W. Li, L. Kui, T. Demetrios, et al., A glimmer of hope: Maintain mitochondrial homeostasis to mitigate Alzheimer’s disease, Aging Dis. 11 (2020) 1260-1275.
    [103]
    R. Grewal, M. Reutzel, B. Dilberger, et al., Purified oleocanthal and ligstroside protect against mitochondrial dysfunction in models of early Alzheimer’s disease and brain ageing, Exp. Neurol. 328 (2020), 113248.
    [104]
    M.P. Singulani, C.P.M. Pereira, A.F.F. Ferreira, et al., Impairment of PGC-1α-mediated mitochondrial biogenesis precedes mitochondrial dysfunction and Alzheimer’s pathology in the 3xTg mouse model of Alzheimer’s disease, Exp. Gerontol. 133 (2020), 110882.
    [105]
    Z. Zhu, L. Xu, D. Cao, et al., Effect of orexin-A on mitochondrial biogenesis, mitophagy and structure in HEK293-APPSWE cell model of Alzheimer’s disease, Clin. Exp. Pharmacol. Physiol. 48 (2021) 355-360.
    [106]
    B. Li, Y. Chen, Y. Zhou, et al., Neural stem cell-derived exosomes promote mitochondrial biogenesis and restore abnormal protein distribution in a mouse model of Alzheimer’s disease, Neural Regen. Res. 19 (2024) 1593-1601.
    [107]
    L. Katsouri, Y.M. Lim, K. Blondrath, et al., PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer’s disease model, Proc. Natl. Acad. Sci. USA 113 (2016) 12292-12297.
    [108]
    J. Wang, M. Guo, Z. Liu, et al., PGC-1α reduces amyloid-β deposition in Alzheimer’s disease: Effect of increased VDR expression, Neurosci. Lett. 744 (2021), 135598.
    [109]
    B. Chen, J. Wu, S. Hu, et al., Apelin-13 improves cognitive impairment and repairs hippocampal neuronal damage by activating PGC-1α/PPARγ signaling, Neurochem. Res. 48 (2023) 1504-1515.
    [110]
    Y.J. Kang, S.J. Hyeon, A. McQuade, et al., Neurotoxic microglial activation via IFNγ-induced Nrf2 reduction exacerbating Alzheimer’s disease, Adv. Sci. (Weinh) 11 (2024), e2304357.
    [111]
    B.N. Lizama, C.T. Chu, Neuronal autophagy and mitophagy in Parkinson’s disease, Mol. Aspects Med. 82 (2021), 100972.
    [112]
    Z. Zhu, C. Yang, A. Iyaswamy, et al., Balancing mTOR signaling and autophagy in the treatment of Parkinson’s disease, Int. J. Mol. Sci. 20 (2019), 728.
    [113]
    A. Sarkar, R. Hameed, A. Mishra, et al., Genetic modulators associated with regulatory surveillance of mitochondrial quality control, play a key role in regulating stress pathways and longevity in C. elegans, Life Sci. 290 (2022), 120226.
    [114]
    E.J. Shin, J.H. Jeong, Y. Hwang, et al., Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson’s disease, Arch. Pharm. Res. 44 (2021) 668-688.
    [115]
    R. MacDonald, K. Barnes, C. Hastings, et al., Mitochondrial abnormalities in Parkinson’s disease and Alzheimer’s disease: Can mitochondria be targeted therapeutically? Biochem. Soc. Trans. 46 (2018) 891-909.
    [116]
    E. Chernivec, J. Cooper, K. Naylor, Exploring the effect of rotenone-a known inducer of Parkinson’s disease-on mitochondrial dynamics in Dictyostelium discoideum, Cells 7 (2018), 201.
    [117]
    B. Zhou, M. Wen, X. Lin, et al., Alpha lipoamide ameliorates motor deficits and mitochondrial dynamics in the Parkinson’s disease model induced by 6-hydroxydopamine, Neurotox. Res. 33 (2018) 759-767.
    [118]
    Q. Zhang, C. Hu, J. Huang, et al., ROCK1 induces dopaminergic nerve cell apoptosis via the activation of Drp1-mediated aberrant mitochondrial fission in Parkinson’s disease, Exp. Mol. Med. 51 (2019) 1-13.
    [119]
    M. Adebayo, S. Singh, A.P. Singh, et al., Mitochondrial fusion and fission: The fine-tune balance for cellular homeostasis, FASEB J. 35 (2021), e21620.
    [120]
    F. Zhao, W. Wang, C. Wang, et al., Mfn2 protects dopaminergic neurons exposed to paraquat both in vitro and in vivo: Implications for idiopathic Parkinson’s disease, Biochim. Biophys. Acta Mol. Basis Dis. 1863 (2017) 1359-1370.
    [121]
    S. Ahmed, M. Kwatra, S. Ranjan Panda, et al., Andrographolide suppresses NLRP3 inflammasome activation in microglia through induction of parkin-mediated mitophagy in in-vitro and in-vivo models of Parkinson disease, Brain Behav. Immun. 91 (2021) 142-158.
    [122]
    G. Ashrafi, J.S. Schlehe, M.J. LaVoie, et al., Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin, J. Cell Biol. 206 (2014) 655-670.
    [123]
    D.A. Madsen, S.I. Schmidt, M. Blaabjerg, et al., Interaction between parkin and α-synuclein in PARK2-mediated Parkinson’s disease, Cells 10 (2021), 283.
    [124]
    Q. Gao, R. Tian, H. Han, et al., PINK1-mediated Drp1S616 phosphorylation modulates synaptic development and plasticity via promoting mitochondrial fission, Signal Transduct. Target. Ther. 7 (2022), 103.
    [125]
    Y. Wang, W. Chen, Y. Han, et al., Neuroprotective effect of engineered Clostridium butyricum-pMTL007-GLP-1 on Parkinson’s disease mice models via promoting mitophagy, Bioeng. Transl. Med. 8 (2023), e10505.
    [126]
    F. De Lazzari, F. Agostini, N. Plotegher, et al., DJ-1 promotes energy balance by regulating both mitochondrial and autophagic homeostasis, Neurobiol. Dis. 176 (2023), 105941.
    [127]
    H. Liu, P.W. Ho, C.T. Leung, et al., Aberrant mitochondrial morphology and function associated with impaired mitophagy and DNM1L-MAPK/ERK signaling are found in aged mutant Parkinsonian LRRK2R1441G mice, Autophagy 17 (2021) 3196-3220.
    [128]
    L.D. Osellame, A.A. Rahim, I.P. Hargreaves, et al., Mitochondria and quality control defects in a mouse model of Gaucher disease: Links to Parkinson’s disease, Cell Metab. 17 (2013) 941-953.
    [129]
    M. Elstner, C.M. Morris, K. Heim, et al., Expression analysis of dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of energy metabolism to cell death, Acta Neuropathol. 122 (2011) 75-86.
    [130]
    A. Bender, K.J. Krishnan, C.M. Morris, et al., High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease, Nat. Genet. 38 (2006) 515-517.
    [131]
    Q. Zheng, H. Liu, H. Zhang, et al., Ameliorating mitochondrial dysfunction of neurons by biomimetic targeting nanoparticles mediated mitochondrial biogenesis to boost the therapy of Parkinson’s disease, Adv. Sci. (Weinh) 10 (2023), e2300758.
    [132]
    Y.L. Hsu, H.J. Chen, J. Gao, et al., Chiisanoside mediates the parkin/ZNF746/PGC-1α axis by downregulating miR-181a to improve mitochondrial biogenesis in 6-OHDA-caused neurotoxicity models in vitro and in vivo: Suggestions for prevention of Parkinson’s disease, Antioxidants (Basel) 12 (2023), 1782.
    [133]
    Z. Sun, X. Ma, H. Yang, et al., Characterization of age-dependent behavior deficits in the PGC-1α knockout mouse, in relevance to the Parkinson’s disease model, Neuroscience 440 (2020) 39-47.
    [134]
    R. Aviner, T.-T. Lee, V.B. Masto, et al., Polyglutamine-mediated ribotoxicity disrupts proteostasis and stress responses in Huntington’s disease, Nat. Cell Biol. 26 (2024) 892-902.
    [135]
    S. Tyebji, A.J. Hannan, Synaptopathic mechanisms of neurodegeneration and dementia: Insights from Huntington’s disease, Prog. Neurobiol. 153 (2017) 18-45.
    [136]
    U. Shirendeb, A.P. Reddy, M. Manczak, et al., Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: Implications for selective neuronal damage, Hum. Mol. Genet. 20 (2011) 1438-1455.
    [137]
    J. Kim, J.P. Moody, C.K. Edgerly, et al., Mitochondrial loss, dysfunction and altered dynamics in Huntington’s disease, Hum. Mol. Genet. 19 (2010) 3919-3935.
    [138]
    A.J. Roe, X. Qi, Drp1 phosphorylation by MAPK1 causes mitochondrial dysfunction in cell culture model of Huntington’s disease, Biochem. Biophys. Res. Commun. 496 (2018) 706-711.
    [139]
    V. Costa, M. Giacomello, R. Hudec, et al., Mitochondrial fission and cristae disruption increase the response of cell models of Huntington’s disease to apoptotic stimuli, EMBO Mol. Med. 2 (2010) 490-503.
    [140]
    W. Song, J. Chen, A. Petrilli, et al., Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity, Nat. Med. 17 (2011) 377-382.
    [141]
    N. Okada, T. Yako, S. Nakamura, et al., Reduced mitochondrial complex II activity enhances cell death via intracellular reactive oxygen species in STHdhQ111 striatal neurons with mutant huntingtin, J. Pharmacol. Sci. 147 (2021) 367-375.
    [142]
    M.E. Solesio, S. Saez-Atienzar, J. Jordan, et al., 3-Nitropropionic acid induces autophagy by forming mitochondrial permeability transition pores rather than activating the mitochondrial fission pathway, Br. J. Pharmacol. 168 (2013) 63-75.
    [143]
    A. Jurcau, Molecular pathophysiological mechanisms in Huntington’s disease, Biomedicines 10 (2022), 1432.
    [144]
    A. Johri, A. Chandra, M. Flint Beal, PGC-1α, mitochondrial dysfunction, and Huntington’s disease, Free Radic. Biol. Med. 62 (2013) 37-46.
    [145]
    T.A. Intihar, E.A. Martinez, R. Gomez-Pastor, Mitochondrial dysfunction in Huntington’s disease; interplay between HSF1, p53 and PGC-1α transcription factors, Front. Cell. Neurosci. 13 (2019), 103.
    [146]
    A. Sharma, T. Behl, L. Sharma, et al., Mitochondrial dysfunction in Huntington’s disease: Pathogenesis and therapeutic opportunities, Curr. Drug Targets 22 (2021) 1637-1667.
    [147]
    R. Li, L. Wang, H.-X. Duan, et al., Regulation of mitochondrial dysfunction induced cell apoptosis is a potential therapeutic strategy for herbal medicine to treat neurodegenerative diseases, Front. Pharmacol. 13 (2022), 937289.
    [148]
    Y. Dong, T. Li, S. Wang, et al., Bu Zhong Yiqi Decoction ameliorates mild cognitive impairment by improving mitochondrial oxidative stress damage via the SIRT3/MnSOD/OGG1 pathway, J. Ethnopharmacol. 331 (2024), 118237.
    [149]
    H.S. Lim, Y.J. Kim, E. Sohn, et al., Bojungikgi-Tang, a traditional herbal formula, exerts neuroprotective effects and ameliorates memory impairments in Alzheimer’s disease-like experimental models, Nutrients 10 (2018), 1952.
    [150]
    Q. Xiao, H. Liu, C. Yang, et al., Bushen-Yizhi formula exerts neuroprotective effect via inhibiting excessive mitophagy in rats with chronic cerebral hypoperfusion, J. Ethnopharmacol. 310 (2023), 116326.
    [151]
    X. Hou, D. Wu, C. Zhang, et al., Bushen-Yizhi formula ameliorates cognition deficits and attenuates oxidative stress-related neuronal apoptosis in scopolamine-induced senescence in mice, Int. J. Mol. Med. 34 (2014) 429-439.
    [152]
    Y. Zhang, H. Sun, X. He, et al., Da-Bu-Yin-Wan and Qian-Zheng-San, two traditional Chinese herbal formulas, up-regulate the expression of mitochondrial subunit NADH dehydrogenase 1 synergistically in the mice model of Parkinson’s disease, J. Ethnopharmacol. 146 (2013) 363-371.
    [153]
    C. Gai, W. Feng, T. Qiang, et al., Da-bu-Yin-Wan and Qian-Zheng-San ameliorate mitochondrial dynamics in the Parkinson’s disease cell model induced by MPP, Front. Pharmacol. 10 (2019), 372.
    [154]
    S. Su, G. Chen, M. Gao, et al., Kai-Xin-San protects against mitochondrial dysfunction in Alzheimer’s disease through SIRT3/NLRP3 pathway, Chin. Med. 18 (2023), 26.
    [155]
    Z. Song, D. Luo, Y. Wang, et al., Neuroprotective effect of Danggui Shaoyao San via the mitophagy-apoptosis pathway in a rat model of Alzheimer’s disease, Evid Based Complement Alternat Med. 2021 (2021), 3995958.
    [156]
    G.S. Chai, J. Gong, J.J. Wu, et al., Danggui Buxue decoction ameliorates mitochondrial biogenesis and cognitive deficits through upregulating histone H4 lysine 12 acetylation in APP/PS1 mice, J. Ethnopharmacol. 313 (2023), 116554.
    [157]
    H. An, C. Lin, C. Gu, et al., Di-Huang-Yi-Zhi herbal formula attenuates amyloid-β-induced neurotoxicity in PC12 cells, Exp. Ther. Med. 13 (2017) 3003-3008.
    [158]
    I.J. Lee, C. Chao, Y. Yang, et al., Huang Lian Jie Du Tang attenuates paraquat-induced mitophagy in human SH-SY5Y cells: A traditional decoction with a novel therapeutic potential in treating Parkinson’s disease, Biomed. Pharmacother. 134 (2021), 111170.
    [159]
    Z. Ji, Y. Shi, X. Li, et al., Neuroprotective effect of Taohong Siwu Decoction on cerebral ischemia/reperfusion injury via mitophagy-NLRP3 inflammasome pathway, Front. Pharmacol. 13 (2022), 910217.
    [160]
    Q. Long, T. Li, Q. Zhu, et al., SuanZaoRen decoction alleviates neuronal loss, synaptic damage and ferroptosis of AD via activating DJ-1/Nrf2 signaling pathway, J. Ethnopharmacol. 323 (2024), 117679.
    [161]
    S. Wen, L. Wang, T. Wang, et al., Puerarin alleviates cadmium-induced mitochondrial mass decrease by inhibiting PINK1-Parkin and Nix-mediated mitophagy in rat cortical neurons, Ecotoxicol. Environ. Saf. 230 (2022), 113127.
    [162]
    Y. Bian, Y. Chen, X. Wang, et al., Oxyphylla A ameliorates cognitive deficits and alleviates neuropathology via the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways in vitro and in vivo murine models of Alzheimer’s disease, J. Adv. Res. 34 (2021) 1-12.
    [163]
    H. Khan, H. Ullah, M. Aschner, et al., Neuroprotective effects of quercetin in Alzheimer’s disease, Biomolecules 10 (2019), 59.
    [164]
    M. Ay, J. Luo, M. Langley, et al., Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson’s disease, J. Neurochem. 141 (2017) 766-782.
    [165]
    D. Lee, N. Kim, S.H. Jeon, et al., Hesperidin improves memory function by enhancing neurogenesis in a mouse model of Alzheimer’s disease, Nutrients 14 (2022), 3125.
    [166]
    S. Kesh, R.R. Kannan, A. Balakrishnan, Naringenin alleviates 6-hydroxydopamine induced Parkinsonism in SHSY5Y cells and zebrafish model, Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 239 (2021), 108893.
    [167]
    N. Wang, H. Wang, Q. Pan, et al., The combination of β-asarone and icariin inhibits amyloid-β and reverses cognitive deficits by promoting mitophagy in models of Alzheimer’s disease, Oxid. Med. Cell. Longev. 2021 (2021), 7158444.
    [168]
    B. Lee, B. Sur, S.G. Cho, et al., Wogonin attenuates hippocampal neuronal loss and cognitive dysfunction in trimethyltin-intoxicated rats, Biomol. Ther. (Seoul) 24 (2016) 328-337.
    [169]
    Y. Zhu, J. Wang, Wogonin increases β-amyloid clearance and inhibits tau phosphorylation via inhibition of mammalian target of rapamycin: Potential drug to treat Alzheimer’s disease, Neurol. Sci. 36 (2015) 1181-1188.
    [170]
    D. Wang, S. Li, W. Wu, et al., Effects of long-term treatment with quercetin on cognition and mitochondrial function in a mouse model of Alzheimer’s disease, Neurochem. Res. 39 (2014) 1533-1543.
    [171]
    Z. He, X. Li, Z. Wang, et al., Protective effects of luteolin against amyloid beta-induced oxidative stress and mitochondrial impairments through peroxisome proliferator-activated receptor γ-dependent mechanism in Alzheimer’s disease, Redox Biol. 66 (2023), 102848.
    [172]
    O.A. Ahmedy, T.M. Abdelghany, M.E.A. El-Shamarka, et al., Apigenin attenuates LPS-induced neurotoxicity and cognitive impairment in mice via promoting mitochondrial fusion/mitophagy: Role of SIRT3/PINK1/Parkin pathway, Psychopharmacology (Berl) 239 (2022) 3903-3917.
    [173]
    X. Yao, J. Zhang, Y. Lu, et al., Myricetin restores Aβ-induced mitochondrial impairments in N2a-SW cells, ACS Chem. Neurosci. 13 (2022) 454-463.
    [174]
    H. Fan, Y. Li, M. Sun, et al., Hyperoside reduces rotenone-induced neuronal injury by suppressing autophagy, Neurochem. Res. 46 (2021) 3149-3158.
    [175]
    H. Bai, Y. Ding, X. Li, et al., Polydatin protects SH-SY5Y in models of Parkinson’s disease by promoting Atg5-mediated but parkin-independent autophagy, Neurochem. Int. 134 (2020), 104671.
    [176]
    X. Song, H. Zhou, Y. Sun, et al., Inhibitory effects of curcumin on H2O2-induced cell damage and APP expression and processing in SH-SY5Y cells transfected with APP gene with Swedish mutation, Mol. Biol. Rep. 47 (2020) 2047-2059.
    [177]
    P.H. Reddy, M. Manczak, X. Yin, et al., Protective effects of a natural product, curcumin, against amyloid ? induced mitochondrial and synaptic toxicities in Alzheimer’s disease, J. Investig. Med. 64 (2016) 1220-1234.
    [178]
    F. Firdaus, M.F. Zafeer, M. Waseem, et al., Ellagic acid mitigates arsenic-trioxide-induced mitochondrial dysfunction and cytotoxicity in SH-SY5Y cells, J. Biochem. Mol. Toxicol. 32 (2018), e22024.
    [179]
    J. He, X. Li, S. Yang, et al., Gastrodin extends the lifespan and protects against neurodegeneration in the Drosophila PINK1 model of Parkinson’s disease, Food Funct. 12 (2021) 7816-7824.
    [180]
    Q. Zhao, Z. Tian, G. Zhou, et al., SIRT1-dependent mitochondrial biogenesis supports therapeutic effects of resveratrol against neurodevelopment damage by fluoride, Theranostics 10 (2020) 4822-4838.
    [181]
    M.F. Zafeer, F. Firdaus, E. Anis, et al., Prolong treatment with Trans-ferulic acid mitigates bioenergetics loss and restores mitochondrial dynamics in streptozotocin-induced sporadic dementia of Alzheimer’s type, Neurotoxicology 73 (2019) 246-257.
    [182]
    D. Wang, L. Cao, X. Zhou, et al., Mitigation of honokiol on fluoride-induced mitochondrial oxidative stress, mitochondrial dysfunction, and cognitive deficits through activating AMPK/PGC-1α/Sirt3, J. Hazard. Mater. 437 (2022), 129381.
    [183]
    R. Li, J. Chen, Salidroside protects dopaminergic neurons by enhancing PINK1/parkin-mediated mitophagy, Oxid. Med. Cell. Longev. 2019 (2019), 9341018.
    [184]
    Y. Tian, Y. Qi, H. Cai, et al., Senegenin alleviates Aβ1-42 induced cell damage through triggering mitophagy, J. Ethnopharmacol. 295 (2022), 115409.
    [185]
    Y. Li, J. Li, L. Yang, et al., Ginsenoside Rb1 protects hippocampal neurons in depressed rats based on mitophagy-regulated astrocytic pyroptosis, Phytomedicine 121 (2023), 155083.
    [186]
    M. Rashedinia, J. Saberzadeh, T. Khosravi Bakhtiari, et al., Glycyrrhizic acid ameliorates mitochondrial function and biogenesis against aluminum toxicity in PC12 cells, Neurotox. Res. 35 (2019) 584-593.
    [187]
    C. Yang, Y. Mo, E. Xu, et al., Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson’s disease mouse model, Int. Immunopharmacol. 75 (2019), 105651.
    [188]
    J. Du, J. Liu, X. Huang, et al., Catalpol ameliorates neurotoxicity in N2a/APP695swe cells and APP/PS1 transgenic mice, Neurotox. Res. 40 (2022) 961-972.
    [189]
    L.F.R. Qi, S. Liu, Y. Liu, et al., Ganoderic acid A promotes amyloid-β clearance (in vitro) and ameliorates cognitive deficiency in Alzheimer’s disease (mouse model) through autophagy induced by activating axl, Int. J. Mol. Sci. 22 (2021), 5559.
    [190]
    L. Chen, L.Y. Horng, C.L. Wu, et al., Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington’s disease, Neuropharmacology 63 (2012) 719-732.
    [191]
    J. Geng, W. Liu, J. Gao, et al., Andrographolide alleviates Parkinsonism in MPTP-PD mice via targeting mitochondrial fission mediated by dynamin-related protein 1, Br. J. Pharmacol. 176 (2019) 4574-4591.
    [192]
    C. Wang, Q. Zou, Y. Pu, et al., Berberine rescues D-ribose-induced Alzheimer’s pathology via promoting mitophagy, Int. J. Mol. Sci. 24 (2023), 5896.
    [193]
    Y. Zhang, J. Wang, C. Wang, et al., Pharmacological basis for the use of evodiamine in Alzheimer’s disease: Antioxidation and antiapoptosis, Int. J. Mol. Sci. 19 (2018), 1527.
    [194]
    F. Meng, J. Wang, F. Ding, et al., Neuroprotective effect of matrine on MPTP-induced Parkinson’s disease and on Nrf2 expression, Oncol. Lett. 13 (2017) 296-300.
    [195]
    L. Cui, Y. Cai, W. Cheng, et al., A novel, multi-target natural drug candidate, matrine, improves cognitive deficits in Alzheimer’s disease transgenic mice by inhibiting Aβ aggregation and blocking the RAGE/Aβ axis, Mol. Neurobiol. 54 (2017) 1939-1952.
    [196]
    Y. Lei, L. Yang, C.Y. Ye, et al., Involvement of intracellular and mitochondrial Aβ in the ameliorative effects of huperzine A against oligomeric Aβ42-induced injury in primary rat neurons, PLoS One 10 (2015), e0128366.
    [197]
    R. Li, Y. Lu, Q. Zhang, et al., Piperine promotes autophagy flux by P2RX4 activation in SNCA/α-synuclein-induced Parkinson disease model, Autophagy 18 (2022) 559-575.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (418) PDF downloads(7) Cited by()
    Proportional views
    Related

    Copyright © Journal of Pharmaceutical Analysis

    E-mail: jpasubmit@126.com;  jpaeditor@xjtu.edu.cn   Tel:+86-029-88960092

    Address: Western China Science and Technology Innovation Harbour, Xixian New Area, Xi’an, 712000, China

    Email alert RSS

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return